INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
0.8941
-0.1359 (-13.19%)
At close: Nov 19, 2026, 4:00 PM EST
0.8975
+0.0034 (0.38%)
After-hours: Nov 19, 2026, 7:51 PM EST
INmune Bio Employees
INmune Bio had 21 employees as of December 31, 2025. The number of employees decreased by 1 or 4.55% compared to the previous year. That makes INmune Bio the 38,283rd largest employer in the world and 5,456th in the United States.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$793,619
Market Cap
27.68M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | 5 | 29.41% | 13 | 9 |
| Dec 31, 2023 | 17 | 7 | 70.00% | 11 | 6 |
| Dec 31, 2022 | 10 | 0 | - | 10 | 0 |
| Dec 31, 2021 | 10 | 5 | 100.00% | 10 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| BriaCell Therapeutics | 31 |
| Filana Therapeutics | 20 |
| Edesa Biotech | 17 |
| Alterity Therapeutics | 11 |
| ProMIS Neurosciences | 11 |
| Marker Therapeutics | 5 |
INMB News
- 6 days ago - INmune Bio price target lowered to $2.50 from $4 at Freedom Broker - TheFly
- 14 days ago - INmune Bio Earnings Call Transcript: Q3 2026 - Transcripts
- 14 days ago - INmune Bio Quarterly report: Q3 2026 - Filings
- 14 days ago - INmune Bio Earnings release: Q3 2026 - Filings
- 14 days ago - INmune Bio reports Q3 EPS (17c), consensus (19c) - TheFly
- 14 days ago - INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 21 days ago - INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th - GlobeNewsWire
- 22 days ago - INmune Bio announces $4.5M registered direct offering - TheFly